# T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

> **NCT06783270** · PHASE1 · RECRUITING · sponsor: **Inge Marie Svane** · enrollment: 10 (estimated)

## Conditions studied

- Melanoma Metastatic

## Interventions

- **BIOLOGICAL:** TIL therapy

## Key facts

- **NCT ID:** NCT06783270
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783270, "T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06783270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*